| Targeting the co-stimulatory receptors 4-1BB, OX40, and GITR of the TNF superfamily holds potential for cancer immunotherapy. |
| Current developments of agonists focus on effective receptor clustering, site-specific activity, and reduced toxicity. |
| A variety of mono- and bispecific antibodies as well as antibody-ligand fusion proteins has been generated, which are now being evaluated in clinical trials. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.